152 related articles for article (PubMed ID: 2145933)
21. [Experience in diagnosis and treatment of asparaginase-associated pancreatitis in children].
Chen Z; Li J
Zhonghua Er Ke Za Zhi; 2014 Nov; 52(11):854-8. PubMed ID: 25582474
[TBL] [Abstract][Full Text] [Related]
22. Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis.
Buie LW; Moore J; van Deventer H
Pharmacotherapy; 2014 Aug; 34(8):e149-51. PubMed ID: 25112526
[TBL] [Abstract][Full Text] [Related]
23. Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs.
Cawley JR; Wright ZM; Meleo K; Post GS; Clifford CA; Vickery KR; Vail DM; Bergman PJ; Thamm DH
J Vet Intern Med; 2020 Mar; 34(2):882-889. PubMed ID: 32064697
[TBL] [Abstract][Full Text] [Related]
24. Asparaginase-associated pancreatitis in a dog.
Schleis SE; Rizzo SA; Phillips JC; LeBlanc AK
Can Vet J; 2011 Sep; 52(9):1009-12. PubMed ID: 22379203
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the results of a L-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemotherapy protocol in dogs with malignant lymphoma.
Piek CJ; Rutteman GR; Teske E
Vet Q; 1999 Apr; 21(2):44-9. PubMed ID: 10321012
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of polyethylene glycol conjugated asparaginase and L-asparaginase for treatment of childhood acute lymphoblastic leukemia].
Cooperation Group of Phase II Clinical Trial of PEG-Asp
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):29-33. PubMed ID: 18512312
[TBL] [Abstract][Full Text] [Related]
27. Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?
MacDonald VS; Thamm DH; Kurzman ID; Turek MM; Vail DM
J Vet Intern Med; 2005; 19(5):732-6. PubMed ID: 16231719
[TBL] [Abstract][Full Text] [Related]
28. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma.
Saba CF; Thamm DH; Vail DM
J Vet Intern Med; 2007; 21(1):127-32. PubMed ID: 17338160
[TBL] [Abstract][Full Text] [Related]
29. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols.
Müller HJ; Löning L; Horn A; Schwabe D; Gunkel M; Schrappe M; von Schütz V; Henze G; Casimiro da Palma J; Ritter J; Pinheiro JP; Winkelhorst M; Boos J
Br J Haematol; 2000 Aug; 110(2):379-84. PubMed ID: 10971395
[TBL] [Abstract][Full Text] [Related]
30. L-asparaginase and PEG asparaginase--past, present, and future.
Keating MJ; Holmes R; Lerner S; Ho DH
Leuk Lymphoma; 1993; 10 Suppl():153-7. PubMed ID: 8481665
[TBL] [Abstract][Full Text] [Related]
31. Pegaspargase: a review of clinical studies.
Graham ML
Adv Drug Deliv Rev; 2003 Sep; 55(10):1293-302. PubMed ID: 14499708
[TBL] [Abstract][Full Text] [Related]
32. Neutropenia associated with vincristine and L-asparaginase induction chemotherapy for canine lymphoma.
Northrup NC; Rassnick KM; Snyder LA; Stone MS; Kristal O; Cotter SM; Moore AS
J Vet Intern Med; 2002; 16(5):570-5. PubMed ID: 12322708
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and adverse events of continuous l-asparaginase administration for canine large cell lymphoma of presumed gastrointestinal origin.
Nakagawa T; Kojima M; Ohno K; Chambers JK; Uchida K; Ohmi A; Goto-Koshino Y; Tomiyasu H; Tsujimoto H
Vet Comp Oncol; 2022 Mar; 20(1):102-108. PubMed ID: 34213084
[TBL] [Abstract][Full Text] [Related]
34. Pegaspargase-induced pancreatitis.
Alvarez OA; Zimmerman G
Med Pediatr Oncol; 2000 Mar; 34(3):200-5. PubMed ID: 10696127
[TBL] [Abstract][Full Text] [Related]
35. [Adverse reactions associated with the use of L-asparaginase during therapy of patients with nB non-Hodgkin's lymphoma. Report of the Polish Paediatric LeuKaemia/Lymphoma Study Group].
Wróbel G; Dobaczewski G; Kazanowska B; Bogusławska-Jaworska J; Balwierz W; Balcerska A; Bubała H; Dluzniewska A; Kołecki P; Kowalczyk J; Kurylak A; Maciejka-Kapuscinska L; Matysiak M; Rokicka-Milewska R; Sońta-Jakimczyk D; Sopyło B; Stefaniak MJ; Stefańska K; Stańczak E; Wysocki M
Med Wieku Rozwoj; 2000; 4(1 Suppl 2):67-72. PubMed ID: 12021464
[TBL] [Abstract][Full Text] [Related]
36. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
37. Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
Vieira Pinheiro JP; Lanversa C; Würthwein G; Beier R; Casimiro da Palma J; von Stackelberg A; Boos J
Leuk Lymphoma; 2002 Oct; 43(10):1911-20. PubMed ID: 12481884
[TBL] [Abstract][Full Text] [Related]
38. [New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase].
Sikorska-Fic B; Makowska K; Rokicka-Milewska R
Wiad Lek; 1998; 51 Suppl 4():233-6. PubMed ID: 10731974
[TBL] [Abstract][Full Text] [Related]
39. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol.
Simon D; Nolte I; Eberle N; Abbrederis N; Killich M; Hirschberger J
J Vet Intern Med; 2006; 20(4):948-54. PubMed ID: 16955821
[TBL] [Abstract][Full Text] [Related]
40. Time Course and Management of Protracted Anaphylaxis Due to PEG-Asparaginase.
Fertal SA; Bradeen HA; Friesen E; Heath JL
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e385-e387. PubMed ID: 32815880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
